MicroRNAs: Short non-coding bullets of gain of function mutant p53 proteins

Oncoscience

Volumn 1, Issue 6, 2014, Pages 427-433

  Donzelli, Sara ^a   Strano, Sabrina ^a   Blandino, Giovanni ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gain of function; MicroRNAs; Mutant p53

Indexed keywords

EID: 84928739238     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.52     Document Type: Article

References (74)

1. Dogini DB, Pascoal VD, Avansini SH, Vieira AS, Pereira TC, Lopes-Cendes I: The new world of RNAs. Genet Mol Biol 2014, 37: 285-293.
2. Paschoal AR, Maracaja-Coutinho V, Setubal JC, Simoes ZL, Verjovski-Almeida S, Durham AM: Non-coding transcription characterization and annotation: a guide and web resource for non-coding RNA databases. RNA Biol 2012, 9: 274-282.
3. Gezer U, Ozgur E, Cetinkaya M, Isin M, Dalay N: Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol Int 2014.
4. Ponting CP, Oliver PL, Reik W: Evolution and functions of long noncoding RNAs. Cell 2009, 136: 629-641.
5. Hirose T, Mishima Y, Tomari Y: Elements and machinery of non-coding RNAs: toward their taxonomy. EMBO Rep 2014, 15: 489-507.
6. Nana-Sinkam SP, Croce CM: Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013, 93: 98-104.
7. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6: 857-866.
8. Di Leva G, Garofalo M, Croce CM: MicroRNAs in cancer. Annu Rev Pathol 2014, 9: 287-314.
9. Di Leva G, Croce CM: miRNA profiling of cancer. Curr Opin Genet Dev 2013, 23: 3-11.
10. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19: 92-105.
11. Carrington JC, Ambros V: Role of microRNAs in plant and animal development. Science 2003, 301: 336-338.
12. Kloosterman WP, Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 2006, 11: 441-450.
13. Calin GA, Croce CM: Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol 2006, 33: 167-173.
14. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10: 704-714.
15. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101: 2999-3004.
16. Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, et al: miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 2012, 3: e423.
17. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, et al: microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006, 103: 9136-9141.
18. Wong KY, Yu L, Chim CS: DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics 2011, 3: 83-92.
19. Davalos V, Esteller M: Rolling the dice to discover the role of DICER in tumorigenesis. Cancer Cell 2012, 21: 717-719.
20. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, Rossi S, Fernandez AF, Carneiro F, Oliveira C, et al: A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 2009, 41: 365-370.
21. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, Fernandez AF, Davalos V, Villanueva A, Montoya G, et al: A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010, 18: 303-315.
22. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302: 1-12.
23. Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, et al: EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal 2010, 3: ra43.
24. Lopez-Serra P, Esteller M: DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 2012, 31: 1609-1622.
25. Selcuklu SD, Donoghue MT, Spillane C: miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 2009, 37: 918-925.
26. Buscaglia LE, Li Y: Apoptosis and the target genes of microRNA-21. Chin J Cancer 2011, 30: 371-380.
27. Li L, Zhou L, Li Y, Lin S, Tomuleasa C: MicroRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homolog. J BUON 2014, 19: 228-236.
28. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010, 411: 846-852.
29. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008, 18: 350-359.
30. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth. Oncogene 2007, 26: 2799-2803.
31. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, et al: EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 2010, 70: 8822-8831.
32. Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449: 682-688.
33. Rotllan N, Fernandez-Hernando C: MicroRNA Regulation of Cholesterol Metabolism. Cholesterol 2012, 2012: 847849.
34. Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC, et al: miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011, 108: 9232-9237.
35. Rager JE, Smeester L, Jaspers I, Sexton KG, Fry RC: Epigenetic changes induced by air toxics: formaldehyde exposure alters miRNA expression profiles in human lung cells. Environ Health Perspect 2011, 119: 494-500.
36. Elamin BK, Callegari E, Gramantieri L, Sabbioni S, Negrini M: MicroRNA response to environmental mutagens in liver. Mutat Res 2011, 717: 67-76.
37. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S: Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 2009, 23: 806-812.
38. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253: 49-53.
39. Hainaut P, Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000, 77: 81-137.
40. Bullock AN, Fersht AR: Rescuing the function of mutant p53. Nat Rev Cancer 2001, 1: 68-76.
41. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nat Genet 1993, 4: 42-46.
42. Oren M, Rotter V: Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010, 2: a001107.
43. Sigal A, Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000, 60: 6788-6793.
44. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G: Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006, 10: 191-202.
45. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, ShiffI, Kogan I, Shay M, Kalo E, et al: Modulation of the vitamin D3 response by cancerassociated mutant p53. Cancer Cell 2010, 17: 273-285.
46. Chicas A, Molina P, Bargonetti J: Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun 2000, 279: 383-390.
47. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, et al: The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neoangiogenesis. Nat Struct Mol Biol 2009, 16: 1086-1093.
48. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD: Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001, 276: 39359-39367.
49. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, et al: Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammationassociated colorectal cancer. Cancer Cell 2013, 23: 634-646.
50. Weissmueller S, Manchado E, Saborowski M, Morris JPt, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, et al: Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor beta Signaling. Cell 2014, 157: 382-394.
51. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, et al: A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137: 87-98.
52. Ali A, Wang Z, Fu J, Ji L, Liu J, Li L, Wang H, Chen J, Caulin C, Myers JN, et al: Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat Commun 2013, 4: 2667.
53. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al: Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148: 244-258.
54. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al: Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 2014, 16: 357-366.
55. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, et al: A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011, 20: 79-91.
56. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G: MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012, 19: 1038-1048.
57. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G: Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 2014, 33: 1601-1608.
58. Muller PA, Trinidad AG, Caswell PT, Norman JC, Vousden KH: Mutant p53 regulates Dicer through p63-dependent and-independent mechanisms to promote an invasive phenotype. J Biol Chem 2014, 289: 122-132.
59. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J, Sakuragi N: Mutant p53 gain-offunction induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013, 32: 3286-3295.
60. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, Callen DF: Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2013, 32: 2992-3000.
61. Subramanian M, Francis P, Bilke S, Li XL, Hara T, Lu X, Jones MF, Walker RL, Zhu Y, Pineda M, et al: A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene 2014.
62. Wang W, Cheng B, Miao L, Mei Y, Wu M: Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis 2013, 4: e574.
63. Brachmann RK: p53 mutants: the achilles' heel of human cancers? Cell Cycle 2004, 3: 1030-1034.
64. Weisz L, Oren M, Rotter V: Transcription regulation by mutant p53. Oncogene 2007, 26: 2202-2211.
65. Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, et al: Expression of TP53 mutationassociated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol 2013, 24: 3082-3088.
66. Di Como CJ, Gaiddon C, Prives C: p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999, 19: 1438-1449.
67. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M, Blandino G: Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000, 275: 29503-29512.
68. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G: Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002, 277: 18817-18826.
69. Strano S, Blandino G: p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. Cell Cycle 2003, 2: 348-349.
70. Guida E, Bisso A, Fenollar-Ferrer C, Napoli M, Anselmi C, Girardini JE, Carloni P, Del Sal G: Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res 2008, 68: 6550-6558.
71. Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, Blandino G: The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle 2008, 7: 3440-3447.
72. Blagosklonny MV: p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominantnegative effect. FASEB J 2000, 14: 1901-1907.
73. Blagosklonny MV: Loss of function and p53 protein stabilization. Oncogene 1997, 15: 1889-1893.
74. Blagosklonny MV, Giannakakou P, Romanova LY, Ryan KM, Vousden KH, Fojo T: Inhibition of HIF-1-and wildtype p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions. Carcinogenesis 2001, 22: 861-867.